[go: up one dir, main page]

NO973933D0 - Vaskulær endotelvekstfaktor B - Google Patents

Vaskulær endotelvekstfaktor B

Info

Publication number
NO973933D0
NO973933D0 NO973933A NO973933A NO973933D0 NO 973933 D0 NO973933 D0 NO 973933D0 NO 973933 A NO973933 A NO 973933A NO 973933 A NO973933 A NO 973933A NO 973933 D0 NO973933 D0 NO 973933D0
Authority
NO
Norway
Prior art keywords
vascular endothelial
polypeptides
growth factor
endothelial growth
vegf
Prior art date
Application number
NO973933A
Other languages
English (en)
Other versions
NO973933L (no
Inventor
Ulf Eriksson
Birgitta Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Helsingfors University Licensi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973933(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Helsingfors University Licensi filed Critical Ludwig Inst Cancer Res
Publication of NO973933D0 publication Critical patent/NO973933D0/no
Publication of NO973933L publication Critical patent/NO973933L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO973933A 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B NO973933L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (2)

Publication Number Publication Date
NO973933D0 true NO973933D0 (no) 1997-08-27
NO973933L NO973933L (no) 1997-09-01

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973933A NO973933L (no) 1995-03-01 1997-08-27 Vaskulær endotelvekstfaktor B

Country Status (14)

Country Link
US (5) US5928939A (no)
EP (1) EP0814827B1 (no)
JP (2) JP3275024B2 (no)
CN (1) CN1146440C (no)
AT (1) ATE245437T1 (no)
AU (1) AU741856B2 (no)
CA (1) CA2211687C (no)
DE (1) DE69629181T2 (no)
DK (1) DK0814827T3 (no)
ES (1) ES2202432T3 (no)
NO (1) NO973933L (no)
NZ (1) NZ305091A (no)
PT (1) PT814827E (no)
WO (1) WO1996026736A1 (no)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434538T2 (de) 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US6734285B2 (en) * 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US7186688B1 (en) * 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US7153827B1 (en) * 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0815221B1 (en) * 1995-03-02 2003-10-22 AMRAD Operations Pty.,Ltd. A novel growth factor and a genetic sequence encoding same
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
WO1997009427A1 (en) 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
DE69638142D1 (de) 1995-09-29 2010-04-15 Univ Siena Regulierte Gene und ihre Verwendungen
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
AU742779B2 (en) * 1996-12-20 2002-01-10 Licentia Oy VEGF-B/receptor complex and uses thereof
WO1998039035A1 (en) 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Method and compositions for healing tissue defects and inducing hypervascularity in mammalian tissue
AU7250298A (en) * 1997-04-25 1998-11-24 Collateral Therapeutics, Inc. Truncated vegf-related proteins
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
CN1295617A (zh) 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
EP2151454B1 (en) 1998-11-10 2012-05-02 Ludwig Institute For Cancer Research Truncated platelet-derived growth factor D, DNA coding therefor, and uses thereof
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
WO2000044903A1 (en) * 1999-01-29 2000-08-03 Ludwig Institute For Cancer Research Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
US7223724B1 (en) * 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
CA2363488A1 (en) * 1999-03-03 2000-09-08 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
WO2000075329A1 (en) * 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis
CA2380072C (en) * 1999-07-28 2007-07-10 John Cooke Nicotine in therapeutic angiogenesis and vasculogenesis
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE60136334D1 (en) * 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
US6965010B2 (en) * 2000-02-25 2005-11-15 Licentia, Ltd. Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
KR20030021159A (ko) * 2000-05-17 2003-03-12 루드빅 인스티튜트 포 캔서 리서치 종양 세포의 존재 검출 및 항-종양제에 대한 스크리닝 방법
US20020068694A1 (en) * 2000-07-26 2002-06-06 Jeltsch Markku Michael Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B
AU8473401A (en) * 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20020151489A1 (en) * 2000-10-02 2002-10-17 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
US6793918B2 (en) * 2000-11-01 2004-09-21 Ludwig Institute For Cancer Research In vivo stimulation of angiogenic activity
CA2431308C (en) * 2000-12-07 2010-04-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AU2002256172A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
DK1385864T3 (da) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
WO2002086497A2 (en) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
CA2451311A1 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
CA2429483A1 (en) * 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030235864A1 (en) * 2002-06-05 2003-12-25 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
EP1912069A3 (en) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
JP4672370B2 (ja) * 2002-12-05 2011-04-20 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
CA2511910A1 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004070018A2 (en) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells
EP3168304A1 (en) 2003-08-27 2017-05-17 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
EP1729750A2 (en) * 2004-03-02 2006-12-13 The Ludwig Institute for Cancer Research Method for inhibiting tumor formation and growth
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
DE602005011943D1 (de) * 2004-04-08 2009-02-05 Sangamo Biosciences Inc Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen
AU2005269265B2 (en) * 2004-08-02 2012-01-12 Zenyth Operations Pty Ltd A method of treating cancer comprising a VEGF-B antagonist
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
JP4988606B2 (ja) * 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
EP1877065A4 (en) * 2005-04-12 2010-12-22 Intradigm Corp COMPOSITION AND METHODS OF RNAI THERAPEUTIC FOR THE TREATMENT OF CANCER AND OTHER VASCULAR TREATMENT DISEASES
ATE502956T1 (de) * 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
EP2548578B1 (en) * 2006-05-17 2014-08-20 The Ludwig Institute for Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
JP2010528647A (ja) * 2007-06-06 2010-08-26 ドマンティス リミテッド ポリペプチド、抗体可変ドメインおよびアンタゴニスト
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
JP5690593B2 (ja) 2007-12-26 2015-03-25 ヴァクシネックス， インコーポレイテッド 抗ｃ３５抗体併用療法および方法
US20110150900A1 (en) * 2008-04-09 2011-06-23 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
KR20160030396A (ko) 2013-07-12 2016-03-17 옵쏘테크 코포레이션 안과적 질환을 치료하거나 예방하기 위한 방법
RU2672377C1 (ru) * 2013-12-18 2018-11-14 СиЭсЭл ЛИМИТЕД Способ лечения ран
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
DE69434538T2 (de) * 1994-03-08 2006-08-10 Human Genome Sciences, Inc. Vaskulärer endothelialer Wachstumsfaktor 2
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
EP0815221B1 (en) * 1995-03-02 2003-10-22 AMRAD Operations Pty.,Ltd. A novel growth factor and a genetic sequence encoding same
CA2224002A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3

Also Published As

Publication number Publication date
JP2000228982A (ja) 2000-08-22
EP0814827A4 (en) 1999-11-10
AU741856B2 (en) 2001-12-13
ES2202432T3 (es) 2004-04-01
US6331301B1 (en) 2001-12-18
WO1996026736A1 (en) 1996-09-06
US20050064493A1 (en) 2005-03-24
AU5302196A (en) 1996-09-18
US5840693A (en) 1998-11-24
CN1176603A (zh) 1998-03-18
DE69629181D1 (de) 2003-08-28
NO973933L (no) 1997-09-01
CA2211687C (en) 2011-05-24
US5928939A (en) 1999-07-27
EP0814827B1 (en) 2003-07-23
JPH10510718A (ja) 1998-10-20
ATE245437T1 (de) 2003-08-15
JP3297687B2 (ja) 2002-07-02
JP3275024B2 (ja) 2002-04-15
DK0814827T3 (da) 2003-11-10
PT814827E (pt) 2003-11-28
CN1146440C (zh) 2004-04-21
DE69629181T2 (de) 2004-05-13
US7341996B2 (en) 2008-03-11
NZ305091A (en) 1998-11-25
US20030170253A1 (en) 2003-09-11
CA2211687A1 (en) 1996-09-06
EP0814827A1 (en) 1998-01-07
HK1008485A1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
NO973933D0 (no) Vaskulær endotelvekstfaktor B
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
ES2141761T3 (es) Secuencias de dna codificantes de nuevos factores de crecimiento/diferenciacion.
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
DK1356052T3 (da) Produktion af hele antistoffer i prokaryotiske celler
DK0713529T3 (da) Vækst-/differentieringsfaktor af TGF-beta-familien
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
AU2002305450A1 (en) Proteomimetic compounds and methods
EP0653940A4 (en) GLIALMITOGENIC FACTORS, THEIR PRODUCTION AND USE.
DE69941791D1 (de) Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
DE69229681D1 (de) Ein protein, das spezifische dna-strukturen erkennt, und seine verwendungen
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
PT714441E (pt) Alergenios recombinantes de cladosporium herbarum
WO2001025437A3 (en) Growth factor polypeptides and nucleic acids encoding same
DE69736325D1 (de) Cr1 fragmente und deren verwendung
MX9802384A (es) Citostatina ii.